The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.
The collaborative effort harnesses Merck's expertise in immuno-oncology and Moderna's innovative mRNA technology to make a meaningful impact on patient outcomes.
/PRNewswire/ The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com s offering..
Citigroup upgraded blue-chip pharma giant Merck & Co., Inc. (NYSE:MRK) to "buy" and hiked its price target to $130, citing "materially revised forecasts" for…
This strategic assessment report, from Markntel Advisors, on Head and Neck Squamous Cell Carcinoma (HNSCC) Market provides a comprehensive analysis that